ISAAA Report Features Updates in Biotech Regulation and Adoption in Asia and Oceania

The global agricultural landscape is shifting, and the Asia-Pacific region is commanding center stage. According to the report ISAAA Brief 57: Global Status of Commercialized Biotech/GM Crops in 2024, Asia has officially become a powerhouse, accounting for nearly 10% of global biotech crop plantings in 2024, with 20.81 million hectares under cultivation. Driven by nine pioneering countries, the region is demonstrating an aggressive growth trajectory. India leads the adoption with its global dominance in Bt cotton, while China accelerates commercial scale-up with massive regulatory approvals for GM maize and soybeans. Meanwhile, Australia has made history by granting the world's first approval for a disease-resistant GM banana alongside climate-resilient crop traits.

However, the Asian biotech landscape reveals considerable variation across neighboring nations. Pakistan and Myanmar have mirrored India's success with GM cotton adoption rates soaring past 94%, while Southeast Asian nations like the Philippines and Vietnam maintain steady, robust momentum in biotech maize. Conversely, the market presents complex challenges, as seen in the decelerating momentum for Bt brinjal in Bangladesh and the relatively low adoption levels in Indonesia.

To help industry leaders, investors, and researchers capitalize on these emerging opportunities, ISAAA released the Biotech Facts and Trends: Asia & Oceania report, which delivers essential adoption information and regulatory analysis. Purchase your copy today for only US$15 from the ISAAA website.